Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
August 14, 2024 08:30 ET
|
Vaccinex, Inc.
Company reviews goals and significance of the clinical trial and outlines development and partnering strategy
Molecular Diagnostics for Neurodegenerative Diseases Technology Research Report 2024-2028 Featuring Synaps Dx, AgenT Biotech, Urvogelbio, Resonant, and Neurodex
August 01, 2024 04:46 ET
|
Research and Markets
Dublin, Aug. 01, 2024 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Neurodegenerative Diseases: Technology Growth Opportunities, 2024-2028" report has been added to ResearchAndMarkets.com's...
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
July 31, 2024 09:00 ET
|
Vaccinex, Inc.
Positive data for SIGNAL-AD trial of Pepinemab in Alzheimer’s Disease affirm expectation of a novel mechanism to delay progression of Alzheimer’s disease
United States Frontotemporal Dementia Market to Experience Steady Growth Through 2028
March 28, 2024 17:56 ET
|
Research and Markets
Dublin, March 28, 2024 (GLOBE NEWSWIRE) -- The "United States Frontotemporal Dementia Market, Competition, Forecast and Opportunities, 2018-2028" report has been added to ResearchAndMarkets.com's...
OrphAI Therapeutics receives Orphan Drug Designation for AIT-101 as a treatment for amyotrophic lateral sclerosis in the European Union
February 15, 2024 10:38 ET
|
OrphAI Therapeutics Inc.
GUILFORD, Conn., Feb. 15, 2024 (GLOBE NEWSWIRE) -- OrphAI Therapeutics Inc. (“OrphAI”), a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today...
Neurodegenerative Disease Market Size To Reach USD 96.4 Billion By 2032 | DataHorizzon Research
February 12, 2024 07:10 ET
|
DataHorizzon Research
Fort Collins, Colorado, Feb. 12, 2024 (GLOBE NEWSWIRE) -- The Neurodegenerative Disease Market size was valued at USD 51.2 Billion in 2023 and is anticipated to reach USD 96.4 Billion by 2032 at a...
Neurodegenerative Disease Market projected to reach USD 69.8 Billion by 2030, growing at a CAGR of 6.2% during the forecast period of 2023-2030 - Claims by MarketDigits in its recent study
November 28, 2023 08:00 ET
|
PIONEERING MARKETDIGITS CONSULTING AND ADVISORY PRIVATE LIMITED
Richmond, Nov. 28, 2023 (GLOBE NEWSWIRE) -- According to a research report "Neurodegenerative Disease Market, By Indication Type (Alzheimer's Disease, Huntington Disease, Multiple Sclerosis,...
Sandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe
September 26, 2023 01:15 ET
|
Novartis Pharma AG
Biosimilar Tyruko® approved for all indications of reference medicine, as first and only biosimilar to treat relapsing forms of multiple sclerosis (MS) in EuropeDecision based on evidence from...
Neuroscience R&D Conference 2023: Unfolding the Recent Advancements in Preclinical and Translational Approaches Treating Neurodegenerative Disorders (London, United Kingdom - October 9-10, 2023)
August 18, 2023 04:13 ET
|
Research and Markets
Dublin, Aug. 18, 2023 (GLOBE NEWSWIRE) -- The "Neuroscience R&D Conference" conference has been added to ResearchAndMarkets.com's offering.Unfolding the recent advancements in preclinical and...
Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab
April 25, 2023 08:00 ET
|
Vaccinex, Inc.
Topline data anticipated in mid-2024 SIGNAL-AD builds on promising data from the Phase 2 SIGNAL Study in Huntington’s Disease ROCHESTER, N.Y., April 25, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc....